Pete Pharma has announced a strategic partnership with Fabrx to bring advanced pharmaceutical 3D printing technology to the compounding pharmacy market in the United States, marking a significant step toward modernizing personalized medicine production. The collaboration aims to transform how compounding pharmacies operate by introducing automation and enhanced customization capabilities to meet diverse patient needs.
Fabrx's pharmaceutical 3D printing platform, already established in hospitals, universities, and clinical research centers globally, offers two primary systems designed for different production scales. The M3DIMAKER 1, featuring a single printhead, serves research purposes and small-batch manufacturing of personalized medicine and medical devices. The more advanced M3DIMAKER 2 employs multiple printheads capable of rapid polypill manufacture for both human and veterinary precision medicine, designed specifically for higher throughput and larger-batch manufacturing requirements. Both systems are supported by proprietary software that facilitates customizable 3D printing, allowing users to select 3D models, prepare printing parameters, and control the printers with precision.
The implementation of pharmaceutical 3D printing technology promises to address several critical challenges facing compounding pharmacies today. Pete Pharma emphasizes that the technology will improve workflow efficiency by automating traditionally laborious processes while enabling greater personalization of medications. The applications span multiple therapeutic areas including pediatrics, lifestyle therapeutics, hormone replacement therapy, and metabolic care, where customized dosing and formulations are particularly valuable.
Beyond technology distribution, Pete Pharma has developed a comprehensive platform utilizing a "pharmacy-first" business model specifically designed to address the unique needs of pharmacies. This approach measures success by the value and outcomes generated through compounded products rather than simply technology adoption. The model prioritizes accessibility for independent pharmacies while reducing the burden of labor and consumable waste, addressing key operational pain points in the compounding pharmacy sector.
"By combining FABRX's proven scientific expertise with Pete Pharma's commercialization strategy, we're making pharmaceutical 3D printing not just possible, but practical and scalable across the U.S. market," Dan Siddall, founder of Pete Pharma, said in a statement.
The partnership enters a growing 3D printing healthcare market that has seen significant developments across various medical applications. Recent industry activity includes restor3d's $38 million funding round in April to launch four new 3D-printed orthopedic product lines, and Lattice Medical's innovative work on 3D-printed breast implants that support tissue regeneration following mastectomy. These advances underscore the expanding role of 3D printing technology in delivering personalized healthcare solutions across multiple specialties.
Click here for the original news story.